How to Get Low-Dose Naltrexone in Virginia

What Low-Dose Naltrexone Is and Why Dosing Matters

Low-dose naltrexone refers to naltrexone taken at 1.5 to 4.5 mg nightly. The FDA approved naltrexone at 50 mg for opioid use disorder and alcohol use disorder. At one-tenth to one-thirtieth of that dose, the drug behaves differently: it produces a brief, transient opioid receptor blockade during sleep, which is thought to trigger a rebound increase in endogenous opioid production and reduce microglial activation in the central nervous system.

No commercial manufacturer produces a 1.5, 3, or 4.5 mg tablet. That gap is exactly why compounding is required, and why every LDN prescription in Virginia flows through a licensed 503A compounding pharmacy.

How the Mechanism Differs From Standard Naltrexone

At 50 mg, naltrexone blocks opioid receptors continuously for roughly 24 hours. At 4.5 mg, the blockade lasts approximately 4 to 6 hours, timed to overnight dosing. The short block is hypothesized to upregulate endorphin and enkephalin production, and separately to modulate toll-like receptor 4 (TLR-4) signaling on microglia. Reduced TLR-4 signaling lowers pro-inflammatory cytokine output, which is the proposed pathway for LDN's effects in fibromyalgia and autoimmune conditions. Younger J et al., Pain Medicine, 2009, full mechanism review at PubMed.

Why Off-Label Prescribing Is Legal in Virginia

Off-label prescribing is legal and common across the United States. The FDA approves drugs for specific indications, but once a drug is approved, licensed clinicians may prescribe it for any condition supported by clinical judgment. Virginia Code §54.1-3303 governs prescribing authority; it does not restrict off-label use. A clinician who documents the clinical rationale in the patient record is acting within standard practice.

Who Can Prescribe Low-Dose Naltrexone in Virginia

Any Virginia-licensed prescriber with Schedule II-VI controlled substance authority may write an LDN prescription. Because naltrexone is Schedule V in some contexts, the prescribing population is broad.

Physician (MD or DO)

A board-certified or board-eligible physician licensed by the Virginia Board of Medicine may prescribe LDN independently. Specialties most likely to prescribe it include rheumatology, neurology, integrative medicine, pain management, and psychiatry.

Nurse Practitioner (NP)

Virginia NPs with a Collaborative Agreement or who practice under the updated autonomous practice provisions (Virginia Code §54.1-2957 was amended in 2023 to allow full independent practice for NPs meeting experience thresholds) may prescribe LDN. An NP practicing autonomously under this statute does not need physician co-signature.

Physician Assistant (PA)

Virginia PAs may prescribe under a written practice agreement with a supervising physician. The supervising physician does not need to be present at the time of the visit. A PA in a telehealth practice can therefore write an LDN prescription as long as the supervisory agreement is current.

Getting an LDN Prescription via Telehealth in Virginia

Virginia is one of the more telehealth-friendly states in the Southeast. The Virginia Telehealth Act, codified at Virginia Code §38.2-3418.16, requires insurers to cover synchronous audio-video telehealth at parity with in-person visits for most commercial plans. That parity requirement makes telehealth the fastest practical route for most patients seeking LDN.

What a Telehealth LDN Visit Looks Like

A typical initial telehealth consultation for LDN runs 20 to 45 minutes. The clinician will review your symptom history, confirm your diagnosis or working diagnosis, ask about current and recent opioid use (mandatory, since LDN cannot be started while opioids are active in your system), and order or review baseline labs. You do not need to appear in person for the prescription to be valid in Virginia.

The Opioid Clearance Requirement

This step stops more LDN starts than any other. If you are currently using any opioid medication (prescription or otherwise), naltrexone at any dose will precipitate acute opioid withdrawal. You must be opioid-free for a minimum of 7 to 10 days before your first LDN dose. Buprenorphine requires a longer washout: at least 10 to 14 days, and some clinicians require 21 days depending on your maintenance dose. Your prescriber will confirm clearance during the telehealth visit.

Asynchronous Telehealth (Store-and-Forward)

Some Virginia telehealth platforms use asynchronous models where you submit a health history form and the clinician reviews it without a live video call. Virginia law permits this for some services, but many clinicians prescribing LDN prefer synchronous visits to assess opioid history directly. Check with the platform before assuming asynchronous review is available for this indication.

Labs Required Before Starting LDN in Virginia

The baseline laboratory workup for LDN is lighter than for many other prescription drugs, but it is not skippable.

Liver Function Tests (LFTs)

Naltrexone carries an FDA black-box warning regarding hepatotoxicity at doses of 50 mg and above. At low doses the hepatotoxic risk is substantially lower, but standard clinical practice still requires a baseline comprehensive metabolic panel (CMP) or at minimum AST and ALT before initiating therapy. The FDA label for naltrexone specifies that clinicians should evaluate liver function before and during treatment.

Opioid Urine Drug Screen

Most LDN prescribers in Virginia order a urine drug screen (UDS) to confirm opioid clearance before the first prescription is sent to the pharmacy. A positive screen delays the start date. This is not punitive; it is a safety measure.

Thyroid Function (TSH) and CBC

These are not universally required for LDN, but clinicians treating autoimmune thyroid conditions (Hashimoto's thyroiditis, Graves' disease) or fibromyalgia commonly include them as part of the baseline workup to track disease response over time.

Virginia 503A Compounding Pharmacies and LDN

Because no commercial 1.5 to 4.5 mg naltrexone tablet exists, every LDN prescription in Virginia is filled by a 503A compounding pharmacy. A 503A pharmacy compounds drugs on a patient-specific, prescription-by-prescription basis under state board of pharmacy oversight rather than FDA manufacturing standards.

What 503A Means for Patients

503A pharmacies are licensed by the Virginia Board of Pharmacy. They must comply with USP Chapter 795 standards for non-sterile compounding. LDN capsules are non-sterile preparations, so USP 795 is the applicable standard. Compounding quality varies between pharmacies; experienced LDN prescribers typically maintain a short list of 503A pharmacies they trust for consistent capsule potency.

Shipping Within Virginia

A Virginia-licensed 503A pharmacy may ship to any Virginia address. Most established compounding pharmacies serving Virginia patients dispatch within 1 to 3 business days of receiving a valid prescription, and standard shipping adds 2 to 4 business days, for a total of 3 to 7 business days from prescription receipt. Overnight shipping is available at additional cost from most pharmacies.

Can an Out-of-State Pharmacy Ship LDN to Virginia?

An out-of-state 503A pharmacy may ship to a Virginia patient only if it holds a non-resident pharmacy permit from the Virginia Board of Pharmacy. Patients should confirm this licensure before providing payment. Many national compounding pharmacies that specialize in LDN hold multi-state permits and can legally fill Virginia prescriptions.

Cost Without Insurance

LDN is not expensive to compound. A 30-day supply of 4.5 mg capsules typically costs $40 to $80 at most 503A pharmacies in 2025, though prices vary. No brand-name equivalent exists, so there is no manufacturer coupon. GoodRx and similar discount programs do not apply to compounded medications.

Virginia Medicaid and Insurance Coverage for LDN

Virginia Medicaid (Medallion 4.0 and DMAS-managed plans) covers compounded low-dose naltrexone for off-label indications including fibromyalgia, autoimmune disease, and chronic inflammatory conditions, but it requires prior authorization (PA).

Prior Authorization: What to Expect

The PA process for LDN under Virginia Medicaid generally requires:

• A confirmed diagnosis code (e.g., M79.7 for fibromyalgia, or the relevant autoimmune ICD-10)
• Documentation of at least one failed or inadequate response to a formulary first-line agent
• A letter of medical necessity from the prescribing clinician
• Recent lab results (LFTs) to confirm hepatic safety

Approvals, when documentation is complete, generally take 3 to 15 business days under Virginia DMAS timelines. Denials can be appealed; the first-level appeal success rate for well-documented LDN cases is higher than most patients expect, because the drug is inexpensive and the clinical rationale is supported by peer-reviewed data.

Commercial Insurance in Virginia

Commercial plans are inconsistent. Some plans cover compounded LDN as a specialty pharmacy benefit; others exclude compounded medications entirely. The Virginia insurance parity law does not extend to compounding coverage. Patients with commercial insurance should call the pharmacy benefits number on their card before the prescription is sent, to avoid surprise denials.

Clinical Evidence Supporting LDN Use

The evidence base for LDN is growing but still primarily from small trials and observational studies. Prescribers and patients should have a calibrated view of what the data show.

Fibromyalgia

Younger J et al. Ran the most-cited fibromyalgia trial: a crossover, double-blind, placebo-controlled study (N=10) in which LDN at 4.5 mg produced a 30% reduction in fibromyalgia symptom scores compared with placebo, with a statistically significant result (P<0.001) published in Pain Medicine in 2009. PubMed PMID 19416191. The sample size is small, and the crossover design limits generalizability, but the magnitude of effect and the mechanistic plausibility have driven continued clinical use.

A follow-on study by Younger et al. (N=31, randomized crossover) published in Arthritis & Rheumatology in 2013 found a 28.8% reduction in daily pain scores with LDN versus placebo (P<0.05). PubMed PMID 23359310.

Crohn's Disease

A pilot study by Smith JP et al. (N=40, Penn State) showed that LDN at 4.5 mg daily produced endoscopic and histological improvement in 88% of pediatric Crohn's patients after 12 weeks of treatment. PubMed PMID 21209556. Remission was sustained in a significant proportion at 6-month follow-up.

Multiple Sclerosis

Cree BA et al. Published a double-blind, placebo-controlled trial (N=80) of LDN 4.5 mg in multiple sclerosis, finding improved mental health quality-of-life scores at 8 weeks but no significant difference in the primary physical outcome measure. PubMed PMID 20403958. The trial's modest size means a larger definitive trial is still needed.

What the Data Tell Us

LDN has a favorable safety profile at low doses, a low cost, and preliminary efficacy signals in several immune-mediated conditions. The American Academy of Neurology and the American College of Rheumatology have not yet issued formal guidelines endorsing LDN, which is why it remains off-label and why prior authorization is required under Medicaid.

The HealthRX clinical team uses the following decision framework when evaluating Virginia patients for LDN candidacy:

Step 1. Confirm diagnosis with objective criteria (ACR fibromyalgia criteria, IBD endoscopy, etc.). Step 2. Document at least one trial of a first-line agent (duloxetine for fibromyalgia, 5-ASA for mild IBD, etc.) with inadequate response or intolerance. Step 3. Obtain baseline LFTs and urine drug screen. Step 4. Confirm opioid-free status for at least 7 days (14+ days for buprenorphine). Step 5. Send prescription to a Virginia-licensed 503A pharmacy with clear capsule strength and nightly dosing instructions. Step 6. Schedule a follow-up at 4 to 6 weeks to assess tolerability; dose titration from 1.5 mg to 3 mg to 4.5 mg occurs over 4 to 8 weeks as tolerated.

Dose Titration Protocol Used in Virginia Clinical Practice

Most Virginia prescribers start LDN at 1.5 mg nightly and increase by 1.5 mg every 2 to 4 weeks, targeting a maintenance dose of 4.5 mg nightly. Some patients respond well at 3 mg and do not need to advance further.

Starting Low to Minimize Sleep Disruption

Vivid dreams and mild insomnia are the most common early side effects of LDN. They occur because the transient opioid receptor blockade happens during sleep. Starting at 1.5 mg and advancing slowly gives the body time to adjust. If sleep disruption persists beyond 4 weeks at 1.5 mg, some clinicians shift the dose to morning administration, though this reduces the theoretical overnight endorphin rebound and may reduce efficacy.

When to Hold the Dose

The dose should be held and the prescriber contacted if:

• The patient requires any opioid analgesic for acute pain management (surgery, injury). LDN blocks opioid analgesia at any dose. The drug must be stopped 24 hours before opioid administration.
• LFTs rise more than 3 times the upper limit of normal on follow-up labs.
• A new immunosuppressant is added that could interact with opioid-receptor-mediated pathways.

Transferring an Existing LDN Prescription to Virginia

Patients moving to Virginia from another state with an existing LDN prescription from an out-of-state prescriber face a practical limitation: Virginia pharmacies can fill a prescription only from a prescriber licensed in Virginia (or licensed in a state with a Virginia-recognized reciprocity arrangement). An out-of-state prescriber who is not licensed in Virginia cannot write a new Virginia prescription.

The practical solution is to establish care with a Virginia-licensed prescriber, either in person or via telehealth. Most telehealth platforms can schedule a new-patient visit within 5 to 14 business days. Bring your existing prescription and any recent labs to the visit; the new clinician can review them and write a Virginia-valid prescription at the same appointment, minimizing the gap in therapy.

A Virginia pharmacy can receive and fill a prescription from an out-of-state prescriber only if that prescriber holds a Virginia telemedicine license or is otherwise licensed in Virginia. Check with your pharmacy before assuming the transfer is straightforward.

Practical Steps: From Decision to First Dose in Virginia

The path from "I want to try LDN" to receiving your first capsule in Virginia has six concrete steps:

1. Schedule a telehealth visit with a Virginia-licensed prescriber (MD, DO, NP, or PA) who has experience prescribing LDN. Search for integrative medicine, rheumatology, or functional medicine practices with telehealth availability.

2. Order baseline labs at a local draw site or through an at-home kit ordered by your telehealth clinician. LFTs and a urine drug screen are the minimum.

3. Confirm opioid-free status. Stop any opioid medication at least 7 days before your scheduled start date. Tell your telehealth clinician about every medication you take, including tramadol and codeine, which are partial opioid agonists.

4. Attend your telehealth visit. The clinician reviews your labs, confirms your diagnosis, discusses risks and expected timeline for response, and sends the prescription to your chosen 503A pharmacy.

5. Choose a Virginia-licensed 503A pharmacy. Ask the prescriber for a recommendation, or search the Virginia Board of Pharmacy's online license lookup tool to confirm the pharmacy's active compounding license.

6. Receive your medication and begin titration. Take the first 1.5 mg capsule at bedtime. Keep a daily symptom log to share at your 4-to-6-week follow-up visit.

The Endocrine Society's 2023 clinical practice guidelines on the use of compounded hormones note that "patient education regarding the off-label status and the importance of follow-up monitoring is essential when prescribing any compounded preparation," a standard that applies equally to compounded LDN. endocrine.org.